You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Related products

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-Cyclin D1 antibody [SP4] (ab16663)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-Cyclin D1 antibody [SP4]
See all Cyclin D1 products (18) ...

Description

Rabbit monoclonal [SP4] to Cyclin D1

Tested applications

ICC/IF, WB, IHC-Pmore details

Cross reactivity

Reacts with

Mouse, Human

Predicted to work with

Rat

Immunogen

Synthetic peptide (Human) (C terminal).

Epitope

C-terminus

Positive control

Breast carcinomas

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: 0.1% Sodium Azide

Purity

Tissue culture supernatant

Clonality

Monoclonal

Clone number

SP4

Isotype

IgG

  • - Cyclin D1 antibody [SP4] (ab16663)- Cyclin D1 antibody [SP4] (ab16663) image (enlarge)

  • Western blot - Cyclin D1 antibody [SP4] (ab16663)Western blot - Cyclin D1 antibody [SP4] (ab16663) image (enlarge)

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Cyclin D1 antibody [SP4] (ab16663)Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Cyclin D1 antibody [SP4] (ab16663) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab16663 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

Essential for the control of the cell cycle at the G1/S (start) transition.

Involvement in disease

Note=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.

Sequence similarities

Belongs to the cyclin family. Cyclin D subfamily.

Post-translational
modifications

Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.

Cellular localization

Nucleus.

Target information above from: UniProt accessionP24385 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • AI327039 antibody
  • B cell ccl/lymphoma 1 antibody
  • B cell CLL/lymphoma 1 antibody
  • B cell leukemia 1 antibody
  • B cell leukemia 1 antibody
  • B cell lymphoma 1 protein antibody
  • B-cell lymphoma 1 protein antibody
  • BCL 1 antibody
  • BCL-1 antibody
  • BCL-1 oncogene antibody
  • BCL1 antibody
  • BCL1 oncogene antibody
  • CCND 1 antibody
  • CCND1 antibody
  • CCND1 protein antibody
  • CCND1/FSTL3 fusion gene, included antibody
  • CCND1/IGHG1 fusion gene antibody
  • CCND1/IGHG1 fusion gene, included antibody
  • CCND1/IGLC1 fusion gene, included antibody
  • CCND1/PTH fusion gene, included antibody
  • CCND1_HUMAN antibody
  • cD1 antibody
  • Cyl 1 antibody
  • D11S287E antibody
  • G1/S specific cyclin D1 antibody
  • G1/S-specific cyclin-D1 antibody
  • Parathyroid adenomatosis 1 antibody
  • PRAD1 antibody
  • PRAD1 oncogene antibody
  • U21B31 antibody
see all

Anti-Cyclin D1 antibody [SP4] images:

  - Cyclin D1 antibody [SP4] (ab16663)

- Cyclin D1 antibody [SP4] (ab16663)

Human mantle cell lymphoma stained with ab16663.

  Western blot - Cyclin D1 antibody [SP4] (ab16663)

Western blot - Cyclin D1 antibody [SP4] (ab16663)

Lane 1 : Anti-Cyclin D1 antibody [SP4] (ab16663) at 1/200 dilution
Lane 2 : Anti-Cyclin D1 antibody [SP4] (ab16663) at 1/400 dilution

Lane 1 : Whole cell lysate prepared from T24 bladder cancer cells
Lane 2 : Whole cell lysate prepared from T24 bladder cancer cells

Lysates/proteins at 25 µg per lane.

Secondary
Goat anti-rabbit IgG conjugated to HRP at 1/5000 dilution
developed using the ECL technique

Performed under reducing conditions.

Predicted band size : 33 kDa
Observed band size : 33 kDa


Exposure time : 10 minutes

Gel run under denaturing conditions 4-12% gradient.

Image kindly supplied by Dr Karin Birkenkamp-Demtroeder through Abreview

See Abreview

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Cyclin D1 antibody [SP4] (ab16663)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Cyclin D1 antibody [SP4] (ab16663)

ab16663 staining Cyclin D1 in Human urinary tract tissue sections by Immunohistochemistry (IHC-P - formaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 10% BSA for 30 minutes at room temperature; antigen retrieval was by heat mediation in citrate buffer. Samples were incubated with primary antibody (1/100 in PBS) for 1 hour. An undiluted HRP-conjugated Goat anti-rabbit IgG polyclonal was used as the secondary antibody.

This image is courtesy of an Abreview submitted by Karin Birkenkamp-Demtroeder

See Abreview

  Western blot - Cyclin D1 antibody [SP4] (ab16663)

Western blot - Cyclin D1 antibody [SP4] (ab16663)

Anti-Cyclin D1 antibody [SP4] (ab16663) at 1/25 dilution + MCF7 cell lysate

Predicted band size : 33 kDa
Observed band size : 33 kDa

References for Anti-Cyclin D1 antibody [SP4] (ab16663)

This product has been referenced in:

  • Read MLet al. Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Res 71:6153-64 (2011). IHC-P; Mouse.Read more (PubMed: 21844185) »
  • Almeida MQet al. Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Hum Mol Genet 19:1387-98 (2010). IHC-P; Mouse.Read more (PubMed: 20080939) »

See all 12 publications for this product

Publishing research using ab16663? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"